Ipsat Therapies Announces Positive Clinical Trial Results for the Prevention of Serious Infections Associated with Antibiotic ResistanceOctober 13, 2003Helsinki, October 13th 2003 - Ipsat Therapies, focused on developing products to prevent the spread of serious infections associated with antibiotic therapy and resistance, today presented positive Phase I clinical trial data for its lead product, P1A, at the BioPartnering Europe Conference in London. This product fulfils many of the criteria for fast track development by the FDA. Antibiotics have long been associated with infections, and bacterial resistance leading to the spread of infections. Commonly known resistant pathogens resulting in these serious infections are Methicillin Resistant Stapholococcus aureus, Clostridium difficile, Vancomycin Resistant Enterococci (VRE) and other gram negative bacteria, as well as aggressive yeasts such as Candida glabrata. The annual cost for treating antibiotic resistance infections is approximately $30 billion in the USA alone. More recently the intestine has been identified as the main source of resistant bacterial strains due to the increased level of bacterial diversity and opportunity for prolonged exposure to antibiotics. Ipsat has now demonstrated that exposure to antibiotic in the intestine causes a depletion of natural microflora and the selective pressure for resistant strains to develop. The problem is compounded in hospitals where containment increases the risk of spread of hospital acquired infections(1) and thus the mortality rate. Ipsat's product is an oral formulation, designed to inactivate beta-lactam antibiotics(2) in the lower intestine, post absorption into the serum. These studies demonstrated the product could successfully remove all non-absorbed, harmful antibiotic residue from the lower intestine without interfering with therapeutic levels in serum and therefore maintaining efficacy. An excellent safety profile and efficacy was demonstrated in all patients treated with the product. Marion Carson, Managing Director at Ipsat, commented on the results: "Decreased investment in the development of new antibiotics in the last ten years has led to a reduction in the number of new antibiotics entering the market, therefore the current goal of the healthcare industry is to prolong the efficacy of existing therapies. Our goal at Ipsat is to extend the utility of current antibiotics and remove the widespread problems associated with resistance and serious infections, often fatal in a growing elderly population, and in hospitals." Ipsat's studies showed that after only three days of exposure to antibiotics, more than 40% of the intestine's microflora are altered and some bacterial strains developed clear resistance to the antibiotic. This was evident also at the genetic level. These changes were seen to last for the duration of antibiotic use and lasted for more than two weeks. The Company has demonstrated in a mouse model that the presence of antibiotics is necessary for intestinal colonisation by VRE, ESBL-Klebsiella pneumoniae and Candida glabrata. Ipsat has also shown in pre-clinical in vivo studies that all these changes are prevented by removal of non-absorbed antibiotic residue from the intestine. The next stage will be a Phase IIa study to evaluate the efficacy of its lead product to prevent antibiotic-induced pathological changes in humans. Ipsat Therapies was granted a licence by the National agency of Medicines in Finland on July 7th 2003 for the GMP production and release of its product for upcoming clinical trials. | |||||||||||||||||||||
|
Related Bacteria Current Events and Bacteria News Articles Metabolic reactions: Less is more in single-celled organisms A Northwestern University study has found a surprising similarity among four quite different organisms. The simplest organism, a bacterium called H. pylori, uses the same number of biochemical reactions (around 300) as yeast, the largest, most complex organism of the group, when optimizing growth. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants Interleukin-12 is a naturally occurring protein essential for the proper functioning of the human immune system. Researchers identify cell group key to Lyme disease arthritis A research team led by the La Jolla Institute for Allergy & Immunology and Albany Medical College has illuminated the important role of natural killer (NK) T cells in Lyme disease, demonstrating that the once little understood white blood cells are central to clearing the bacterial infection and reducing the intensity and duration of arthritis associated with Lyme disease. Blood tests can help detect presence of necrotizing soft tissue infections With less than half of patients with necrotizing soft tissue infections displaying the physical signs of these very serious infections, researchers have found two simple blood tests can help physicians diagnose what is commonly known as "flesh-eating bacteria," according to a study in the December issue of The American Journal of Surgery. Vaccine and drug research aimed at ticks and mosquitoes to prevent disease transmission Most successful vaccines and drugs rely on protecting humans or animals by blocking certain bacteria from growing in their systems. But, a new theory actually hopes to take stopping infectious diseases such as West Nile virus and Malaria to the next level by disabling insects from transmitting these viruses. Research in twins defines shared features of the human gut microbial communities: variations linked to obesity Trillions of microbes make their home in the gut, where they help to break down and extract energy and nutrients from the food we eat. Yet, scientists have understood little about how this distinctive mix of microbes varies from one individual to the next. Rivers are carbon processors, not inert pipelines Microorganisms in rivers and streams play a crucial role in the global carbon cycle that has not previously been considered. Vitamin D found to fight placental infection In a paper available at the online site of the journal Biology of Reproduction, a team of UCLA researchers reports for the first time that vitamin D induces immune responses in placental tissues by stimulating production of the antimicrobial protein cathelicidin. CSHL scientists discover a new way in which epigenetic information is inherited Hereditary information flows from parents to offspring not just through DNA but also through the millions of proteins and other molecules that cling to it. Researchers identify how binge drinking may drive heart disease As the holidays arrive, a group of researchers has identified the precise mechanisms by which binge drinking contributes to clogs in arteries that lead to heart attack and stroke, according to a study published today in the journal Atherosclerosis. More Bacteria Current Events and Bacteria News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||